7,789 reports of this reaction
2.0% of all INSULIN GLARGINE reports
#9 most reported adverse reaction
HYPOGLYCAEMIA is the #9 most commonly reported adverse reaction for INSULIN GLARGINE, manufactured by sanofi-aventis U.S. LLC. There are 7,789 FDA adverse event reports linking INSULIN GLARGINE to HYPOGLYCAEMIA. This represents approximately 2.0% of all 399,332 adverse event reports for this drug.
Patients taking INSULIN GLARGINE who experience hypoglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOGLYCAEMIA is a less commonly reported adverse event for INSULIN GLARGINE, but still significant enough to appear in the safety profile.
In addition to hypoglycaemia, the following adverse reactions have been reported for INSULIN GLARGINE:
The following drugs have also been linked to hypoglycaemia in FDA adverse event reports:
HYPOGLYCAEMIA has been reported as an adverse event in 7,789 FDA reports for INSULIN GLARGINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOGLYCAEMIA accounts for approximately 2.0% of all adverse event reports for INSULIN GLARGINE, making it a notable side effect.
If you experience hypoglycaemia while taking INSULIN GLARGINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.